Published in Ann Rheum Dis on July 08, 2004
Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol (2006) 2.78
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther (2005) 1.85
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol (2006) 1.56
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J (2007) 1.19
Glomerulonephritis, Th1 and Th2: what's new? Clin Exp Immunol (2005) 1.10
Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol (2011) 1.07
Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature. Case Rep Neurol Med (2013) 1.00
Perioperative management of medications used in the treatment of rheumatoid arthritis. HSS J (2006) 0.96
Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther (2008) 0.91
Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. Clin Rheumatol (2005) 0.90
Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int (2007) 0.84
Sulfatide attenuates experimental Staphylococcus aureus sepsis through a CD1d-dependent pathway. Infect Immun (2013) 0.83
TNFR1 signaling kinetics: spatiotemporal control of three phases of IKK activation by posttranslational modification. Cell Signal (2013) 0.82
Antitumor necrosis factor-induced neutropenia: a case report with double positive rechallenges. Clin Rheumatol (2006) 0.82
Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom. Clin Rheumatol (2015) 0.78
Cutaneous abnormalities in rheumatoid arthritis compared with non-inflammatory rheumatic conditions. Ann Rheum Dis (2006) 0.78
Decreased serum cell-free DNA levels in rheumatoid arthritis. Auto Immun Highlights (2015) 0.78
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine (2017) 0.78
Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. BMJ (2005) 0.77
Cardiovascular co-morbidity in patients with rheumatic diseases. Arthritis Res Ther (2011) 0.77
Etanercept-associated transient bone marrow aplasia: a review of the literature and pathogenetic mechanisms. Drugs R D (2014) 0.77
Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C. World J Clin Cases (2016) 0.76
[Risk of infection during treatment with tumor necrosis factor-alpha inhibitors]. Z Rheumatol (2006) 0.76
Long-term use of adalimumab in the treatment of rheumatic diseases. Open Access Rheumatol (2009) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 16.12
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell (1989) 10.98
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med (2000) 10.21
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum (2003) 8.50
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum (2003) 5.29
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet (2002) 4.68
Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum (2001) 4.60
Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis (2003) 4.53
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) (2003) 3.70
Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum (2002) 3.63
Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis (2002) 3.10
Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA (1993) 2.98
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet (2001) 2.71
Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 2.68
Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol (2003) 2.67
Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum (2003) 2.57
Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology (Oxford) (2002) 2.53
All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol (2003) 2.52
Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum (2002) 2.32
Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol (2003) 2.16
Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum (2002) 2.12
Cause of death in rheumatoid arthritis. Br J Rheumatol (1984) 2.12
Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation (1996) 2.10
Limitations and strengths of spontaneous reports data. Clin Ther (1998) 1.84
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol (2002) 1.83
Onset of multiple sclerosis associated with anti-TNF therapy. Neurology (2001) 1.73
Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc (2001) 1.70
Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. J Rheumatol (2002) 1.61
Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab. Rheumatology (Oxford) (2003) 1.59
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum (2003) 1.58
The molecular action of tumor necrosis factor-alpha. Eur J Biochem (1991) 1.52
Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med (2003) 1.51
Anti-tumor necrosis factor therapy and Listeria monocytogenes infection: report of two cases. Arthritis Rheum (2002) 1.51
Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. Ann Rheum Dis (2002) 1.49
Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med (2003) 1.47
Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factor-alpha-deficient mice. Lab Invest (1999) 1.41
[Fatal miliary tuberculosis during treatment with infliximab]. Ned Tijdschr Geneeskd (2002) 1.37
Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol (2000) 1.33
Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol (2003) 1.32
Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum (2003) 1.31
Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest (2003) 1.30
Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. Arthritis Rheum (2004) 1.27
Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol (2003) 1.17
Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis (2004) 1.17
Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum (2002) 1.11
The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol (2002) 1.05
New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis (2002) 0.99
Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med (2003) 0.99
Concurrence of rheumatoid arthritis and systemic lupus erythematosus: report of 11 cases. Ann Rheum Dis (1987) 0.98
Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ (2003) 0.98
Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus (2002) 0.97
Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis (2002) 0.97
Pneumocystis carinii pneumonia following a second infusion of infliximab. Rheumatology (Oxford) (2002) 0.97
Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J (2002) 0.96
Leukocytoclastic vasculitis due to etanercept. J Rheumatol (2000) 0.95
Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol (2003) 0.95
Reactivation of histoplasmosis after treatment with infliximab. Am J Med (2002) 0.94
Anti-tumor necrosis factor therapies. Curr Opin Rheumatol (2001) 0.94
Viral pneumonia as a serious complication of etanercept therapy. Ann Intern Med (2002) 0.94
The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. Clin Exp Rheumatol (2002) 0.93
Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J (2002) 0.91
Coexistent rheumatoid arthritis and systemic lupus erythematosus: clinical, serological, and phenotypic features. Ann Rheum Dis (1992) 0.91
Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis. Ann Rheum Dis (2002) 0.91
Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy. Am J Ophthalmol (2002) 0.91
Mycobacteria tuberculosis peritonitis associated with etanercept therapy. Clin Exp Rheumatol (2003) 0.91
Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: some explanations and suggestions for future studies. Clin Exp Rheumatol (1997) 0.89
Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. Arthritis Rheum (2003) 0.88
Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol (2002) 0.88
Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) (2001) 0.88
The role of TNFalpha and lymphotoxin in demyelinating disease. Ann Rheum Dis (1999) 0.87
Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol (2002) 0.87
Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum (2001) 0.87
Post-mortem collection of human joint tissues for research. Rheumatology (Oxford) (2003) 0.86
Pulmonary miliary tuberculosis in a patient with anti-TNF-alpha treatment. Scand J Rheumatol (2002) 0.86
Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol (2003) 0.86
Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med (1999) 0.85
Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol (2003) 0.84
Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis. Rheumatology (Oxford) (2002) 0.84
Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. Arthritis Rheum (2002) 0.82
Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology (Oxford) (2003) 0.81
Dermatological complications of etanercept therapy for rheumatoid arthritis. Br J Dermatol (2002) 0.81
Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford) (2003) 0.80
Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford) (2003) 0.80
Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system. Ann Rheum Dis (2000) 0.78
Panniculitis: a presenting manifestation of disseminated histoplasmosis in a patient with rheumatoid arthritis. J Clin Rheumatol (2003) 0.78
Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. Del Med J (2000) 0.76
Silent thyroiditis associated with etanercept in rheumatoid arthritis. Ann Rheum Dis (2002) 0.76
Neck mass in a rheumatoid arthritis patient taking etanercept. J Clin Rheumatol (2000) 0.76
Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. Clin Exp Rheumatol (2003) 0.76
Miliary tuberculosis after biological therapy for rheumatoid arthritis. Rheumatology (Oxford) (2002) 0.76
Tuberculous tonsillitis in a patient receiving etanercept treatment. Ann Rheum Dis (2003) 0.76
Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum (2000) 6.88
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis (2009) 5.82
Outcome of low back pain in general practice: a prospective study. BMJ (1998) 5.27
Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. Arthritis Rheum (2001) 4.85
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. Br J Rheumatol (1994) 3.82
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2006) 3.73
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2007) 3.34
The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res (1996) 3.25
Estimating the prevalence of low back pain in the general population. Evidence from the South Manchester Back Pain Survey. Spine (Phila Pa 1976) (1995) 3.18
Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16
Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. Arthritis Rheum (2003) 2.97
Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum (1997) 2.90
A comparison of the performance of different methods of disease classification for rheumatoid arthritis. Results of an analysis from a nationwide twin study. J Rheumatol (1994) 2.87
Widespread body pain and mortality: prospective population based study. BMJ (2001) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Sjögren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol (1998) 2.67
The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. Rheumatology (Oxford) (2006) 2.66
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis (2009) 2.65
Predicting who develops chronic low back pain in primary care: a prospective study. BMJ (1999) 2.62
Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol (1993) 2.56
Role of mechanical and psychosocial factors in the onset of forearm pain: prospective population based study. BMJ (2000) 2.56
Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS Study Group. European Prospective Osteoporosis Study Group. Osteoporos Int (2000) 2.52
Age-sex registers as a screening tool for general practice: size of the wrong address problem. Br Med J (Clin Res Ed) (1984) 2.51
Estimating the prevalence of delayed median nerve conduction in the general population. Br J Rheumatol (1998) 2.50
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum (2007) 2.46
Occupational risk factors for shoulder pain: a systematic review. Occup Environ Med (2000) 2.40
Development and validation of a questionnaire to assess disabling foot pain. Pain (2000) 2.34
Prevalence of shoulder pain in the community: the influence of case definition. Ann Rheum Dis (1997) 2.28
The prevalence and associated features of chronic widespread pain in the community using the 'Manchester' definition of chronic widespread pain. Rheumatology (Oxford) (1999) 2.21
Influence of previous pain experience on the episode incidence of low back pain: results from the South Manchester Back Pain Study. Pain (1996) 2.17
Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor? Rheumatology (Oxford) (2007) 2.15
A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13
Musculoskeletal pain is associated with a long-term increased risk of cancer and cardiovascular-related mortality. Rheumatology (Oxford) (2009) 2.09
Differences in the characteristics of responders and non-responders in a prevalence survey of vertebral osteoporosis. European Vertebral Osteoporosis Study Group. Osteoporos Int (1995) 2.09
Risk factors for neck pain: a longitudinal study in the general population. Pain (2001) 2.06
Psychosocial factors in the workplace--do they predict new episodes of low back pain? Evidence from the South Manchester Back Pain Study. Spine (Phila Pa 1976) (1997) 2.01
Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis (2008) 2.01
Is musculoskeletal pain more common now than 40 years ago?: Two population-based cross-sectional studies. Rheumatology (Oxford) (2005) 1.99
Psychologic distress and low back pain. Evidence from a prospective study in the general population. Spine (Phila Pa 1976) (1995) 1.98
Relation of risk of systemic lupus erythematosus to west African admixture in a Caribbean population. Hum Genet (2003) 1.97
Radiographic osteoarthritis of the knee classified by the Ahlbäck and Kellgren & Lawrence systems for the tibiofemoral joint in people aged 35-54 years with chronic knee pain. Ann Rheum Dis (1997) 1.95
Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum (1999) 1.94
Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) (2008) 1.91
Chronic widespread pain in the community: the influence of psychological symptoms and mental disorder on healthcare seeking behavior. J Rheumatol (1999) 1.90
Regional differences in survival from cancer. Community Med (1981) 1.85
Widespread pain: is an improved classification possible? J Rheumatol (1996) 1.83
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum (1999) 1.79
Clinical signs of early osteoarthritis: reproducibility and relation to x ray changes in 541 women in the general population. Ann Rheum Dis (1991) 1.79
Estimating the incidence of rheumatoid arthritis: trying to hit a moving target? Arthritis Rheum (1999) 1.78
Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (1998) 1.76
The influence of work related psychosocial factors and psychological distress on regional musculoskeletal pain: a study of newly employed workers. J Rheumatol (2001) 1.72
Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum (2001) 1.71
The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum (2001) 1.71
The grading of hallux valgus. The Manchester Scale. J Am Podiatr Med Assoc (2001) 1.70
Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70
Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol (1996) 1.67
Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) (1999) 1.66
The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. American Rheumatism Association. J Rheumatol (1998) 1.63
Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. Ann Rheum Dis (2009) 1.63
The pill, parity, and rheumatoid arthritis. Arthritis Rheum (1990) 1.62
Low back pain in schoolchildren: the role of mechanical and psychosocial factors. Arch Dis Child (2003) 1.61
The distribution, determinants, and clinical correlates of vertebral osteophytosis: a population based survey. J Rheumatol (1999) 1.60
The Norfolk Arthritis Register (NOAR). Clin Exp Rheumatol (2004) 1.60
Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum (1987) 1.60
Investigating the HLA component in rheumatoid arthritis: an additive (dominant) mode of inheritance is rejected, a recessive mode is preferred. Genet Epidemiol (1991) 1.60
Self-reported dark red bleeding as a marker comparable with occult blood testing in screening for large bowel neoplasms. Br J Surg (1983) 1.59
Number and type of vertebral deformities: epidemiological characteristics and relation to back pain and height loss. European Vertebral Osteoporosis Study Group. Osteoporos Int (1999) 1.59
Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum (2002) 1.58
Chronic widespread pain is associated with slower cognitive processing speed in middle-aged and older European men. Pain (2010) 1.58
Employment and physical work activities as predictors of future low back pain. Spine (Phila Pa 1976) (1997) 1.57
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRB1*04-bearing haplotypes in rheumatoid arthritis patients. Arthritis Rheum (1996) 1.56
Low prevalence of rheumatoid arthritis in black-Caribbeans compared with whites in inner city Manchester. Ann Rheum Dis (1994) 1.55
Risk factors for persistent chronic widespread pain: a community-based study. Rheumatology (Oxford) (2001) 1.55
Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol (2006) 1.53
Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: findings of a population-based prospective cohort study. Arthritis Rheum (2007) 1.53
Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology (Oxford) (2002) 1.53
Occupational factors related to shoulder pain and disability. Occup Environ Med (1997) 1.49
Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann Rheum Dis (2007) 1.47
Evaluation of work-related psychosocial factors and regional musculoskeletal pain: results from a EULAR Task Force. Ann Rheum Dis (2008) 1.46
Chronic widespread pain in the population: a seven year follow up study. Ann Rheum Dis (2002) 1.45
Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45
Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum (1999) 1.45
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) (2010) 1.44